• Explore /
  • Poster
  • / Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.

Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.

Abstract Poster

Authors

Sang Hoon Chun

Sang Hoon Chun

Division of Hematology/Oncology, Department of Internal Medicine, Bucheon St.Mary's hospital, Catholic University of Korea, Bucheon-Si, South Korea;

Sang Hoon Chun , Jung Hoon Kim , Seung-Jin Kwag , Myoung Hee Kang , Ji-Ho Park , Gyeong-Won Lee , Jung Hun Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 157)

DOI

10.1200/JCO.2023.41.4_suppl.157

Abstract #

157

Poster Bd #

H16

Abstract Disclosures

Similar Posters

First Author: Hideaki Bando

First Author: Xin Qu

First Author: Carlos Alberto Mayo

First Author: Masato Nakamura